{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:29:24Z","timestamp":1776698964971,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After the ESOPEC trial showed a survival benefit for fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)-treated adenocarcinomas of the esophagus (EAC) and the gastroesophageal junction (GEJ) compared with Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS), a European, high-volume center study for stage cT2cN0 EAC and GEJ was undertaken, as it has been published that a third of these patients are understaged and could benefit from a multimodal approach<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of prospective databases from ten high-volume European centers was performed. Inclusion criteria were GEJ Siewert type I\/II or EAC with cT2cN0 status at diagnosis undergoing multimodal treatment with FLOT or CROSS. Primary endpoint was overall survival (OS)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2012 and 2023, 133 patients met the inclusion criteria, of whom 73 (54.9%) received CROSS and 60 (45.1%) underwent treatment with FLOT. In both groups, patients were mainly male (p = 0.08), older than 70 years (p = 0.24), and had American Society of Anesthesiologists (ASA) II classification (p = 0.45). Regarding surgical treatment, more patients underwent gastrectomy in the FLOT than in the CROSS cohort (23.3% versus 6.8%, p = 0.007). There were no differences regarding pT, pN, and pM category (p &gt; 0.05). Median survival was not reached, while mean survival was 74.6 months (95% CI 60.5\u201388.7 months) for CROSS versus 100.8 months (95% CI 72.5\u201394.5 months, p = 0.028) for FLOT. The 3-year survival was 87% in the FLOT group versus 59% in the CROSS group. In multivariable analyses, FLOT was independent factor for survival (p &lt; 0.001)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For cT2cN0 staged EAC and GEJ type I \/II patients FLOT chemotherapy showed a survival benefit and should be the preferred treatment in a multimodal approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18311-8","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:29:50Z","timestamp":1760369390000},"page":"10128-10136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of Pretreatment Strategies for cT2cN0 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A European High-Volume Center Cohort Analysis"],"prefix":"10.1245","volume":"32","author":[{"given":"Naita M.","family":"Wirsik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cezanne D.","family":"Kooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Dempster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerma","family":"Crnovrsanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel E.","family":"Donlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eren","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Bhanot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Nienh\u00fcser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Polette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kammy","family":"Kewani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Grimminger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Reim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans F.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne S.","family":"Gisbertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph-Thomas","family":"Germer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle P.","family":"Ruurda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Klevebro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John V.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark I.","family":"Van Berge Henegouwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheraz","family":"Markar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Van Hillegersberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane J.","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"12","key":"18311_CR1","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17(12):1697\u2013708. https:\/\/doi.org\/10.1016\/S1470-2045(16)30531-9.","journal-title":"Lancet Oncol"},{"issue":"22","key":"18311_CR2","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med"},{"issue":"5","key":"18311_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/SLA.0000000000005617","volume":"276","author":"NE Donlon","year":"2022","unstructured":"Donlon NE, Moran B, Kamilli A, et al. CROSS versus FLOT regimens in esophageal and esophagogastric junction adenocarcinoma: a propensity-matched comparison. Ann Surg. 2022;276(5):792\u20138. https:\/\/doi.org\/10.1097\/SLA.0000000000005617.","journal-title":"Ann Surg"},{"issue":"3","key":"18311_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.29271\/jcpsp.2021.03.326","volume":"31","author":"I Karadag","year":"2021","unstructured":"Karadag I, Karakaya S, Ates O, Cakmak Oksuzoglu OB. CROSS or FLOT in distal esophageal and gastroesophageal cancer. J Coll Physicians Surg Pak. 2021;31(3):326\u20139. https:\/\/doi.org\/10.29271\/jcpsp.2021.03.326.","journal-title":"J Coll Physicians Surg Pak."},{"key":"18311_CR5","doi-asserted-by":"publisher","unstructured":"Oesophago-Gastric Anastomotic Audit (OGAA) Collaborative. Postoperative and pathological outcomes of CROSS and FLOT as neoadjuvant therapy for esophageal and junctional adenocarcinoma: an international cohort study from the oesophagogastric anastomosis audit (OGAA). Ann Surg. 2023;277(5):e1026\u201334. https:\/\/doi.org\/10.1097\/SLA.0000000000005394.","DOI":"10.1097\/SLA.0000000000005394"},{"issue":"8","key":"18311_CR6","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1245\/s10434-017-5827-1","volume":"24","author":"MCJ Anderegg","year":"2017","unstructured":"Anderegg MCJ, van der Sluis PC, Ruurda JP, et al. Preoperative chemoradiotherapy versus perioperative chemotherapy for patients with resectable esophageal or gastroesophageal junction adenocarcinoma. Ann Surg Oncol. 2017;24(8):2282\u201390. https:\/\/doi.org\/10.1245\/s10434-017-5827-1.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"18311_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jso.24596","volume":"115","author":"L Goense","year":"2017","unstructured":"Goense L, van der Sluis PC, van Rossum PSN, et al. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: a propensity score-matched analysis comparing toxicity, pathologic outcome, and survival. J Surg Oncol. 2017;115(7):812\u201320. https:\/\/doi.org\/10.1002\/jso.24596.","journal-title":"J Surg Oncol"},{"key":"18311_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","volume":"16","author":"J Hoeppner","year":"2016","unstructured":"Hoeppner J, Lordick F, Brunner T, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016;16:503.","journal-title":"BMC Cancer"},{"issue":"4","key":"18311_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2409408.","journal-title":"N Engl J Med"},{"key":"18311_CR10","doi-asserted-by":"publisher","unstructured":"Obermannov\u00e1 RL, Leong T, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO clinical practice guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open. 2025;10(2):104134. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104134.","DOI":"10.1016\/j.esmoop.2025.104134"},{"issue":"3","key":"18311_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s10120-014-0403-x","volume":"18","author":"M Moehler","year":"2015","unstructured":"Moehler M, Baltin CT, Ebert M, et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 2015;18(3):550\u201363. https:\/\/doi.org\/10.1007\/s10120-014-0403-x.","journal-title":"Gastric Cancer"},{"issue":"12","key":"18311_CR12","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1245\/s10434-014-3929-6","volume":"21","author":"TJ Hardacker","year":"2014","unstructured":"Hardacker TJ, Ceppa D, Okereke I, et al. Treatment of clinical T2N0M0 esophageal cancer. Ann Surg Oncol. 2014;21(12):3739\u201343. https:\/\/doi.org\/10.1245\/s10434-014-3929-6.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"18311_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.athoracsur.2019.04.008","volume":"108","author":"B Kidane","year":"2019","unstructured":"Kidane B, Korst RJ, Weksler B, et al. Neoadjuvant therapy vs upfront surgery for clinical T2N0 esophageal cancer: a systematic review. Ann Thorac Surg. 2019;108(3):935\u201344. https:\/\/doi.org\/10.1016\/j.athoracsur.2019.04.008.","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"18311_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1136\/gut.2010.228254","volume":"60","author":"WH Allum","year":"2011","unstructured":"Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449\u201372. https:\/\/doi.org\/10.1136\/gut.2010.228254.","journal-title":"Gut"},{"issue":"4","key":"18311_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/dote.12334","volume":"29","author":"JP Dolan","year":"2016","unstructured":"Dolan JP, Kaur T, Diggs BS, et al. Significant understaging is seen in clinically staged T2N0 esophageal cancer patients undergoing esophagectomy. Dis Esophagus. 2016;29(4):320\u20135. https:\/\/doi.org\/10.1111\/dote.12334.","journal-title":"Dis Esophagus"},{"issue":"5","key":"18311_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ejso.2018.02.005","volume":"44","author":"L Goense","year":"2018","unstructured":"Goense L, Visser E, Haj Mohammad N, et al. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: a population-based cohort study. Eur J Surg Oncol. 2018;44(5):620\u20135. https:\/\/doi.org\/10.1016\/j.ejso.2018.02.005.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"18311_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/SLA.0000000000006478","volume":"280","author":"NM Wirsik","year":"2024","unstructured":"Wirsik NM, Kooij CD, Dempster N, et al. Optimal treatment strategies for cT2 staged adenocarcinoma of the esophagus and the gastroesophageal junction: a multinational, high-volume center retrospective cohort analysis. Ann Surg. 2024;280(5):799\u2013807. https:\/\/doi.org\/10.1097\/SLA.0000000000006478.","journal-title":"Ann Surg"},{"key":"18311_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejca.2015.11.024","volume":"56","author":"SR Markar","year":"2016","unstructured":"Markar SR, Gronnier C, Pasquer A, et al. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. Eur J Cancer. 2016;56:59\u201368. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.024.","journal-title":"Eur J Cancer"},{"issue":"7","key":"18311_CR19","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1245\/s10434-010-1024-1","volume":"17","author":"TW Rice","year":"2010","unstructured":"Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721\u20134. https:\/\/doi.org\/10.1245\/s10434-010-1024-1.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"18311_CR20","first-page":"38","volume":"79","author":"AE Abouleish","year":"2015","unstructured":"Abouleish AE, Leib ML, Cohen NH. ASA provides examples to each ASA physical status class. ASA Newsletter. 2015;79(6):38\u201349.","journal-title":"ASA Newsletter."},{"issue":"4","key":"18311_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/ALN.0000000000001541","volume":"126","author":"EE Hurwitz","year":"2017","unstructured":"Hurwitz EE, Simon M, Vinta SR, et al. Adding examples to the ASA-physical status classification improves correct assignment to patients. Anesthesiology. 2017;126(4):614\u201322. https:\/\/doi.org\/10.1097\/ALN.0000000000001541.","journal-title":"Anesthesiology"},{"issue":"3","key":"18311_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/anae.14569","volume":"74","author":"D Mayhew","year":"2019","unstructured":"Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status\u2014historical perspectives and modern developments. Anaesthesia. 2019;74(3):373\u20139. https:\/\/doi.org\/10.1111\/anae.14569.","journal-title":"Anaesthesia"},{"issue":"2","key":"18311_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg"},{"issue":"10184","key":"18311_CR24","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet."},{"key":"18311_CR25","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090\u20138.","journal-title":"Lancet Oncol"},{"key":"18311_CR26","doi-asserted-by":"publisher","unstructured":"Wolfson P, Ho KMA, Bassett P, et al. Accuracy of clinical staging for T2N0 oesophageal cancer: systematic review and meta-analysis. Dis Esophagus. 2021;34(8):doab002. https:\/\/doi.org\/10.1093\/dote\/doab002","DOI":"10.1093\/dote\/doab002"},{"key":"18311_CR27","doi-asserted-by":"publisher","unstructured":"Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, ESMO Guidelines Working Group. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.\u00a0Ann Oncol. 2013. https:\/\/doi.org\/10.1093\/annonc\/mdt342","DOI":"10.1093\/annonc\/mdt342"},{"issue":"28","key":"18311_CR28","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1200\/JCO.23.00139","volume":"41","author":"JL Moore","year":"2023","unstructured":"Moore JL, Green M, Santaolalla A, et al. Pathologic lymph node regression after neoadjuvant chemotherapy predicts recurrence and survival in esophageal adenocarcinoma: a multicenter study in the United Kingdom. J Clin Oncol. 2023;41(28):4522\u201334. https:\/\/doi.org\/10.1200\/JCO.23.00139.","journal-title":"J Clin Oncol"},{"key":"18311_CR29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11700-3","author":"W Schroeder","year":"2022","unstructured":"Schroeder W, Ghadimi MPH, Schloesser H, et al. Long-term outcome after histopathological complete response with and without nodal metastases following multimodal treatment of esophageal cancer. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-11700-3.","journal-title":"Ann Surg Oncol"},{"key":"18311_CR30","unstructured":"Pathological response guides adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in surgically resected gastro-oesophageal cancer (SPACE-FLOT): international cohort study. Br J Surg 2025; 112."},{"key":"18311_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3892\/ol.2025.15039","volume":"29","author":"A Lin","year":"2025","unstructured":"Lin A, Song L, Wang Y, et al. Future prospects of deep learning in esophageal cancer diagnosis and clinical decision support (review). Oncol Lett. 2025;29:293.","journal-title":"Oncol Lett"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18311-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18311-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18311-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:17:28Z","timestamp":1762352248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18311-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["18311"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18311-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hans Fuchs\u2014Intuitive: educational grant, Stryker: consulting, Medtronic: Advisory Board, Distalmotion: Consulting, Suzanne Gisbertz\u2014Consultant for J&J, Medicaroid and Olympus, Mark van Berge Henegouwen\u2014proctor for Intuitive and consultant for Johnson & Johnson, BBraun, Stryker and Medtronic. All fees paid to institution. Christiane J. Bruns\u2014consultant for Johnson & Johnson","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and its later versions. Informed consent or substitutes were obtained from all the patients for inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}